Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we dive into the rapidly advancing world of in-vivo CAR therapies. What began as an ambitious workaround to ex-vivo manufacturing is now transforming into a programmable platform for immune modulation. From CD4/CD8 tuning to redosable vectors and tissue-selective delivery, the field is converging on something much bigger than oncology.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!
Enough shilling for the day, lots to cover this week, let's get started!
This week, we're unpacking the most important signal in cell therapy you might have missed: in-vivo CAR platforms are no longer speculative. According to the 2025 Global Report for In-Vivo CAR Cell Therapy from Novotech, over 70 disclosed assets are now in play, spanning oncology, autoimmunity, and beyond.
In-vivo CAR therapies are no longer theoretical.
Human dosing has begun.
Platforms like Umoja's VivoVec and Myeloid's LNP programs are now in first-in-human trials, and as we noted above, there are over 70 disclosed assets racing through preclinical development. With assets in development expected to cross 100 in 2025, the space is moving faster than many realize.
What’s emerging isn’t just a replacement for ex-vivo CAR-T, it’s an entirely new category of immunologic programming.
Today is more of an advanced discussion. We encourage those looking for the basics to checkout our previous writings on the topic - here.
Also, we have written a few threads that have gone viral which you can see below:
The Era of In-Vivo CAR-T Has Arrived
The Next Decade of In-Vivo CAR-T (2025–2035)
And more….search out timeline on twitter - we share quite a bit of interesting content on the topic.
However, today we are going to focus on some of the emerging approaches taking place in the field. These are not mainstream ideas….yet. It will be a bit technical, but we promise interesting. Topics will include:
Beyond CAR-T
Delivery considerations beyond targeting
Immune cloaking (with CD47)
Viral / Non-viral CAR-T combo sequencing
Programming PK
Leveraging geography for speed
What comes next?
Let’s get to it!
CARs Can Now Target Specific Cell Subtypes…and That Changes Everything
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.